Form 4: Vertex Pharmaceuticals SVP Kristen Ambrose Reports Stock Transactions
SEC Form 4 Filing
Kristen Ambrose, SVP & Chief Accounting Officer of Vertex Pharmaceuticals, reports the disposition of shares of common stock on February 24 and 25, 2025.
Summary
- Kristen Ambrose, SVP & Chief Accounting Officer of Vertex Pharmaceuticals, reported changes in beneficial ownership of the company's stock.
- On February 24, 2025, 828 shares of common stock were disposed of at a price of $483.28.
- On February 25, 2025, 884 shares of common stock were disposed of at a price of $480.95.
- Following these transactions, Ms. Ambrose beneficially owns 9,086 shares of Vertex Pharmaceuticals common stock.
- The transactions were made pursuant to a company-approved trading plan under Rule 10b5-1, which was entered into on August 8, 2024.
Sentiment
Score: 5
Explanation: This is a neutral filing, simply reporting stock transactions. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This filing is a routine disclosure of stock transactions by a company insider, as required by the SEC. It provides transparency into the trading activities of key personnel at Vertex Pharmaceuticals.
Stakeholder Impact
- The stock transactions by a company insider may be of interest to shareholders.
Key Dates
| Date | Description |
|---|---|
| 08/08/2024 | Date of entry into Rule 10b5-1 trading plan |
| 02/24/2025 | Date of transaction: Disposition of 828 shares |
| 02/25/2025 | Date of transaction: Disposition of 884 shares |
| 02/26/2025 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.